These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27409720)

  • 21. EEG Brain Wave Activity at Rest and during Evoked Attention in Children with Attention-Deficit/Hyperactivity Disorder and Effects of Methylphenidate.
    Thomas BL; Viljoen M
    Neuropsychobiology; 2016; 73(1):16-22. PubMed ID: 26812442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Misuse of Methylphenidate.
    Clemow DB
    Curr Top Behav Neurosci; 2017; 34():99-124. PubMed ID: 26695166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Methylphenidate in Brazil: a decade of publications].
    Itaborahy C; Ortega F
    Cien Saude Colet; 2013 Mar; 18(3):803-16. PubMed ID: 23546207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A reply concerning scientologists and ADHD: Scientific evidence and indications for treatment with methylphenidate].
    Zetterström R
    Lakartidningen; 2002 Mar; 99(14):1618-9. PubMed ID: 12025221
    [No Abstract]   [Full Text] [Related]  

  • 26. The potential for misuse and abuse of medications in ADHD: a review.
    Clemow DB; Walker DJ
    Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.
    Tan M; Appleton R
    Arch Dis Child; 2005 Jan; 90(1):57-9. PubMed ID: 15613514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The early history of the neuroscience of attention-deficit/hyperactivity disorder.
    Baumeister AA; Henderson K; Pow JL; Advokat C
    J Hist Neurosci; 2012 Jul; 21(3):263-79. PubMed ID: 22724488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ADHD, Ritalin, and big brother.
    Miller AL
    Altern Med Rev; 2000 Oct; 5(5):401. PubMed ID: 11056410
    [No Abstract]   [Full Text] [Related]  

  • 31. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689
    [No Abstract]   [Full Text] [Related]  

  • 32. An experimental comparison of Pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
    Tenenbaum S; Paull JC; Sparrow EP; Dodd DK; Green L
    J Atten Disord; 2002 Sep; 6(2):49-60. PubMed ID: 12142861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal methylphenidate (Daytrana) for ADHD.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An examination of the effects of stimulant medication on response inhibition: a comparison between children with and without attention deficit hyperactivity disorder.
    Brackenridge R; McKenzie K; Murray GC; Quigley A
    Res Dev Disabil; 2011; 32(6):2797-804. PubMed ID: 21700419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of methylphenidate on spatial attention asymmetry in adolescents with attention deficit hyperactivity disorder (ADHD): preliminary findings.
    Silk TJ; Newman DP; Eramudugolla R; Vance A; Bellgrove MA
    Neuropsychologia; 2014 Apr; 56():178-83. PubMed ID: 24486422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of children with Williams syndrome with methylphenidate.
    Bawden HN; MacDonald GW; Shea S
    J Child Neurol; 1997 Jun; 12(4):248-52. PubMed ID: 9203066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of methylphenidate treatment outcome in adults with attention-deficit/hyperactivity disorder (ADHD).
    Retz W; Retz-Junginger P
    Eur Arch Psychiatry Clin Neurosci; 2014 Nov; 264 Suppl 1():S35-43. PubMed ID: 25231833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.